Trials / Completed
CompletedNCT00895713
Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation
Efficacy and Safety of Intramuscular Hepatitis B Virus Immune Globulin Grifols for the Prevention of Hepatitis B Virus Recurrence After Orthotopic Liver Transplantation.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Instituto Grifols, S.A. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if treatment with intramuscular hepatitis B virus immune globulin Grifols, a new specific hepatitis B immune globulin, is effective and safe for the prevention of hepatitis B virus recurrence after orthotopic liver transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intramuscular hepatitis B virus immune globulin | Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2005-06-01
- Completion
- 2005-07-01
- First posted
- 2009-05-08
- Last updated
- 2009-05-08
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00895713. Inclusion in this directory is not an endorsement.